Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00754364 | Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients | terminated | Phase 2 | 108 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02967133 | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | terminated | Phase 2 | 7 | Alliance Foundation Trials, LLC.OTHER | 1 | Sep 8, 2022 | clinicaltrials |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers |
| terminated |
| Phase 1 |
| 14 |
| AbbVieINDUSTRY |
| 5 |
| Sep 8, 2022 |
| clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy(NAC-PNP) | terminated | N/A | 69 | Rijnstate HospitalOTHER | 1 | Aug 25, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | terminated | Phase 1 | 111 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 15, 2022 | clinicaltrials |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | terminated | Phase 2 | 9 | Helix BioPharma CorporationINDUSTRY | 2 | Aug 12, 2022 | clinicaltrials |
| NCT02400814 | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | terminated | Phase 1 | 27 | Megan Daly, MDOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT04069936 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC | terminated | Phase 2 | 19 | WindMIL TherapeuticsINDUSTRY | 1 | Aug 2, 2022 | clinicaltrials |
| NCT04560686 | Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 28, 2022 | clinicaltrials |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents(MLAPOCHI) | terminated | Phase 2 | 1 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor | terminated | Phase 2 | 3 | Nasser Hanna, M.D.OTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03209128 | Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala(IPC) | terminated | — | 11 | Centre Francois Baclesse, LuxembourgOTHER | 1 | Jun 23, 2022 | clinicaltrials |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | terminated | Phase 2 | 21 | University of WashingtonOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT03091491 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03711422 | Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | terminated | Phase 1 | 2 | National Cancer Centre, SingaporeOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma | terminated | Phase 1 | 9 | Augusta UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03904108 | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy | terminated | Phase 2 | 3 | ROGER S KERESZTES MDOTHER | 1 | May 26, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT01487174 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy | terminated | Phase 3 | 8 | Kadmon Corporation, LLCINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | terminated | Phase 4 | 81 | Radboud University Medical CenterOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT02705404 | A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing | terminated | — | 8 | Mayo ClinicOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03054038 | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 22 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03754244 | A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics | terminated | Phase 1 | 1 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 1 | 16 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02932345 | Gefitinib Long-term Survivor Study | terminated | — | 59 | AstraZenecaINDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer(ILIAD) | terminated | Phase 1 | 21 | MendusINDUSTRY | 1 | Mar 16, 2022 | clinicaltrials |
| NCT02459067 | ImmuniCell® in Patients With Advanced Cancers | terminated | Phase 2 | 8 | TC BiopharmINDUSTRY | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02323126 | Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer | terminated | Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 8 | Feb 28, 2022 | clinicaltrials |
| NCT04958993 | A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 7 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT03988192 | Volatile Organic Compounds in Exhaled Air and Sweat of Patients Treated by Immunotherapy for Lung Cancer: Research on Biomarkers for Early Therapeutic Response(Immuno-VOC) | terminated | N/A | 60 | Hopital FochOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT03255083 | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 13 | Daiichi SankyoINDUSTRY | 1 | Jan 19, 2022 | clinicaltrials |
| NCT02963610 | Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT00372073 | Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | terminated | Phase 2 | 187 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT00885963 | A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer | terminated | Phase 2 | 62 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 22, 2021 | clinicaltrials |
| NCT03990077 | Study of HL-085 Plus Docetaxel in Patients With KRAS Mutant NSCLC | terminated | Phase 1 | 2 | Shanghai Kechow Pharma, Inc.INDUSTRY | 1 | Dec 10, 2021 | clinicaltrials |
| NCT00960297 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | terminated | Phase 2 | 4 | SCRI Development Innovations, LLCOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04165031 | A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation | terminated | Phase 1 / Phase 2 | 5 | Eli Lilly and CompanyINDUSTRY | 2 | Nov 24, 2021 | clinicaltrials |
| NCT03998189 | Metabolic and Microbial Profiling of Lung Cancer | terminated | N/A | 1 | Wake Forest University Health SciencesOTHER | 1 | Nov 5, 2021 | clinicaltrials |
| NCT01741155 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | terminated | Phase 2 | 34 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 13, 2021 | clinicaltrials |
| NCT01799135 | Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC) | terminated | N/A | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC(SHERLOC) | terminated | Phase 2 | 153 | Elevation OncologyINDUSTRY | 6 | Oct 12, 2021 | clinicaltrials |
| NCT01288430 | A Study of DS-2248 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03624907 | Daily vs. Non-Daily SBRT for NSCLC | terminated | N/A | 20 | University of FloridaOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03131206 | A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | terminated | Phase 1 / Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02408016 | Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma | terminated | Phase 1 / Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 13, 2021 | clinicaltrials |
| NCT03200600 | Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery | terminated | Phase 4 | 126 | Peking University First HospitalOTHER | 1 | Jul 13, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Sep 10, 2022source: clinicaltrials